Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Change in Accured Expenses (2016 - 2025)

Agios Pharmaceuticals (AGIO) has disclosed Change in Accured Expenses for 13 consecutive years, with $8.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Accured Expenses fell 34.68% year-over-year to $8.9 million, compared with a TTM value of -$790000.0 through Dec 2025, down 121.39%, and an annual FY2025 reading of -$790000.0, down 121.39% over the prior year.
  • Change in Accured Expenses was $8.9 million for Q4 2025 at Agios Pharmaceuticals, up from $1.9 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $14.5 million in Q2 2025 and bottomed at -$26.1 million in Q1 2025.
  • Average Change in Accured Expenses over 5 years is $705200.0, with a median of $1.7 million recorded in 2022.
  • The sharpest move saw Change in Accured Expenses surged 2034.18% in 2023, then plummeted 364.03% in 2024.
  • Year by year, Change in Accured Expenses stood at $2.7 million in 2021, then plummeted by 77.73% to $594000.0 in 2022, then soared by 2034.18% to $12.7 million in 2023, then rose by 6.92% to $13.6 million in 2024, then tumbled by 34.68% to $8.9 million in 2025.
  • Business Quant data shows Change in Accured Expenses for AGIO at $8.9 million in Q4 2025, $1.9 million in Q3 2025, and $14.5 million in Q2 2025.